Japanese Journal of Clinical Oncology · 2014 · 22 citations · 21 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyChemotherapy Drug AdministrationChemotherapy Toxicity ManagementCombination ChemotherapyDose SchedulingTopoisomerase InhibitorsToxicity ManagementChemotherapy Dose OptimizationIrinotecan-based TherapySecond-line ChemotherapySmall Cell Lung Cancer TherapySmall Cell Lung Cancer TreatmentTopoisomerase I InhibitorsWeekly Scheduling
OBJECTIVE: Irinotecan is a potent inhibitor of deoxyribonucleic acid topoisomerase 1 and the weekly schedule of 100-125 or 350 mg/m(2) administration on Day 1 every 3 weeks is recommended for recurrent small cell lung cancer. However, severe gastrointestinal toxic effects and myelosuppression are often observed in this dose setting. We conducted a retrospective study to evaluate the efficacy and safety of low-dose irinotecan monotherapy (60 mg/m(2) on Days 1, 8 and 15 every 4 weeks) as second-line chemotherapy for small cell lung cancer. METHODS: The medical charts of small cell lung cancer patients who had received second-line chemotherapy at the National Cancer Center Hospital East between April 2003 and June 2012 were reviewed. Consecutive 57 patients who were treated with low dose of irinotecan (60 mg/m(2) on Days 1, 8 and 15 every 4 weeks) were analyzed in this study. RESULTS: Median age was 70 years (range, 51-83). Fifty-two (91%) were male, 36 (63%) had an Eastern Cooperative Oncology Group performance status 0-1 and 26 (46%) were sensitive relapse. The median number of chemotherapy cycles was 2. The objective response rate was 32% (95% confidence interval: 20-45%).The median progression-free survival and the median overall survival were 2.9 months (95% confidence interval: 1.9-3.4 months) and 5.3 months (95% confidence interval: 3.6-7.6 months), respectively. The incidence of Grade 3/4 neutropenia, diarrhea and nausea/vomiting was 21, 4 and 5%, respectively. CONCLUSIONS: Low-dose irinotecan monotherapy for recurrent small cell lung cancer might be effective with favorable toxicity. Randomized trial of 60 mg/m(2) versus standard dose of irinotecan is warranted.
21
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2013 · 11.9K citations · Full text
Yukio Ando, Hideo Saka, Maki Ando et al. · PubMed · 2000 · 788 citations
Medicine, Genetics, Pharmacology +15